NO963919L - Isolerte peptider avledet fra MAGE-tumorrejeksjonsantigenforlöpere som komplekserer med HLA-A2-molekyler - Google Patents
Isolerte peptider avledet fra MAGE-tumorrejeksjonsantigenforlöpere som komplekserer med HLA-A2-molekylerInfo
- Publication number
- NO963919L NO963919L NO963919A NO963919A NO963919L NO 963919 L NO963919 L NO 963919L NO 963919 A NO963919 A NO 963919A NO 963919 A NO963919 A NO 963919A NO 963919 L NO963919 L NO 963919L
- Authority
- NO
- Norway
- Prior art keywords
- hla
- molecules
- complex
- peptides derived
- isolated peptides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/217,186 US5585461A (en) | 1994-03-24 | 1994-03-24 | Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof |
US08/261,160 US5591430A (en) | 1994-03-24 | 1994-06-17 | Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof |
US08/290,381 US5851523A (en) | 1994-03-24 | 1994-08-15 | Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof |
PCT/US1995/003657 WO1995025740A1 (en) | 1994-03-24 | 1995-03-22 | Isolated peptides derived from mage tumor rejection antigen precursors which complex with hla-a2 molecules |
Publications (2)
Publication Number | Publication Date |
---|---|
NO963919D0 NO963919D0 (no) | 1996-09-19 |
NO963919L true NO963919L (no) | 1996-11-20 |
Family
ID=27396385
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO963919A NO963919L (no) | 1994-03-24 | 1996-09-19 | Isolerte peptider avledet fra MAGE-tumorrejeksjonsantigenforlöpere som komplekserer med HLA-A2-molekyler |
Country Status (16)
Country | Link |
---|---|
US (1) | US5851523A (zh) |
EP (2) | EP0960622A3 (zh) |
JP (1) | JP3536179B2 (zh) |
CN (1) | CN1151170C (zh) |
AT (1) | ATE198336T1 (zh) |
AU (1) | AU698781B2 (zh) |
CA (1) | CA2186004C (zh) |
DE (1) | DE69519748T2 (zh) |
DK (1) | DK0804483T3 (zh) |
ES (1) | ES2154728T3 (zh) |
FI (1) | FI963779A0 (zh) |
GR (1) | GR3035636T3 (zh) |
NO (1) | NO963919L (zh) |
NZ (1) | NZ283587A (zh) |
PT (1) | PT804483E (zh) |
WO (1) | WO1995025740A1 (zh) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6723832B1 (en) * | 1996-10-03 | 2004-04-20 | Ludwig Institute For Cancer Research | Isolated peptides corresponding to amino acid sequences of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof |
US5686068A (en) * | 1994-03-24 | 1997-11-11 | Ludwig Institute For Cancer Research | Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof |
US5587289A (en) * | 1995-03-14 | 1996-12-24 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof |
US5821122A (en) * | 1995-06-07 | 1998-10-13 | Inserm (Institute Nat'l De La Sante Et De La Recherche . .) | Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof |
DE69610483T2 (de) * | 1996-01-18 | 2001-06-13 | Aventis Pharma Deutschland Gmbh | In kunstlisches Rekombinantes Substrat rAGG-1 und nativem Aggrecan zum Studium der proteolytischen Wirkung von 'Aggrecanase' in Zellkultursystemen |
CA2295321C (en) * | 1997-06-23 | 2008-01-29 | Ludwig Institute For Cancer Research | Isolated nona- and decapeptides which bind to hla molecules, and the use thereof |
US6060284A (en) | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
US6716809B1 (en) | 1997-09-12 | 2004-04-06 | Ludwig Institute For Cancer Research | Mage-A3 peptides presented by HLA class molecules |
US5965535A (en) | 1997-09-12 | 1999-10-12 | Ludwig Institute For Cancer Research | Mage-3 peptides presented by HLA class II molecules |
US6291430B1 (en) | 1997-09-12 | 2001-09-18 | Ludwig Institute For Cancer Research | Mage-3 peptides presented by HLA class II molecules |
GB9826143D0 (en) | 1998-11-27 | 1999-01-20 | Ludwig Inst Cancer Res | Tumour rejection antigens |
EP1905832A3 (en) * | 1999-09-09 | 2009-09-09 | Schering Corporation | Mammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions |
ATE389019T1 (de) * | 1999-09-09 | 2008-03-15 | Schering Corp | Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen |
US7090847B1 (en) * | 1999-09-09 | 2006-08-15 | Schering Corporation | Mammalian cytokines; related reagents and methods |
US6897288B1 (en) | 1999-10-19 | 2005-05-24 | Ludwig Institute For Cancer Research | Mage-A12 antigenic peptides and uses thereof |
KR20020047249A (ko) * | 1999-10-19 | 2002-06-21 | 에드워드 에이. 맥더모트, 주니어 | Mage-a12 항원성 펩티드 및 그의 용도 |
CA2408328C (en) | 2000-05-10 | 2012-04-17 | Aventis Pasteur Limited | Immunogenic polypeptides encoded by mage minigenes and uses thereof |
US7049413B2 (en) | 2001-05-18 | 2006-05-23 | Ludwig Institute For Cancer Research | MAGE-A3 peptides presented by HLA class II molecules |
US20030113919A1 (en) * | 2001-08-17 | 2003-06-19 | Aventis Pasteur, Ltd. | Immunogenic targets for melanoma |
US7786278B2 (en) | 2002-04-09 | 2010-08-31 | Sanofi Pasteur Limited | Modified CEA nucleic acid and expression vectors |
US20040223949A1 (en) * | 2002-10-22 | 2004-11-11 | Sunnybrook And Women's College Health Sciences Center Aventis Pasteur, Ltd. | Vaccines using high-dose cytokines |
JP4668919B2 (ja) * | 2003-10-08 | 2011-04-13 | サノフィ パストゥール インコーポレイテッド | 修飾cea/b7ベクター |
AU2008303948A1 (en) * | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Use of the peptide Asn-Asp-Asp-Cys-Glu- Leu-Cys-Val-Asn-Val-Ala-Cys-Thr-Gly-Cys-Leu alone or in combination with the peptide Thr-Thr-Ser-Gln-Val- Arg-Pro-Arg as a therapeutic agent |
CN106117334B (zh) * | 2016-06-24 | 2020-02-11 | 秦皇岛未名健康城开发有限公司 | 一种肿瘤抗原mage3的ctl识别表位肽及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5342774A (en) * | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
CA2141960A1 (en) * | 1992-08-07 | 1994-02-17 | Ralph T. Kubo | Hla binding peptides and their uses |
US5519117A (en) * | 1992-12-22 | 1996-05-21 | Ludwig Institute For Cancer Research | Isolated, tyrosinase derived peptides and uses thereof |
CA2157510A1 (en) * | 1993-03-05 | 1994-09-15 | Howard M. Grey | Hla-a2.1 binding peptides and their uses |
-
1994
- 1994-08-15 US US08/290,381 patent/US5851523A/en not_active Expired - Lifetime
-
1995
- 1995-03-22 ES ES95914838T patent/ES2154728T3/es not_active Expired - Lifetime
- 1995-03-22 PT PT95914838T patent/PT804483E/pt unknown
- 1995-03-22 NZ NZ283587A patent/NZ283587A/en not_active IP Right Cessation
- 1995-03-22 CN CNB951922610A patent/CN1151170C/zh not_active Expired - Lifetime
- 1995-03-22 EP EP99200031A patent/EP0960622A3/en not_active Withdrawn
- 1995-03-22 AU AU21928/95A patent/AU698781B2/en not_active Expired
- 1995-03-22 JP JP52482295A patent/JP3536179B2/ja not_active Expired - Lifetime
- 1995-03-22 CA CA002186004A patent/CA2186004C/en not_active Expired - Lifetime
- 1995-03-22 DK DK95914838T patent/DK0804483T3/da active
- 1995-03-22 EP EP95914838A patent/EP0804483B1/en not_active Expired - Lifetime
- 1995-03-22 DE DE69519748T patent/DE69519748T2/de not_active Expired - Lifetime
- 1995-03-22 AT AT95914838T patent/ATE198336T1/de active
- 1995-03-22 WO PCT/US1995/003657 patent/WO1995025740A1/en active IP Right Grant
-
1996
- 1996-09-19 NO NO963919A patent/NO963919L/no unknown
- 1996-09-23 FI FI963779A patent/FI963779A0/fi unknown
-
2001
- 2001-03-26 GR GR20010400481T patent/GR3035636T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
CA2186004A1 (en) | 1995-09-28 |
DE69519748T2 (de) | 2001-10-18 |
EP0960622A3 (en) | 1999-12-22 |
NZ283587A (en) | 1998-04-27 |
NO963919D0 (no) | 1996-09-19 |
CN1151170C (zh) | 2004-05-26 |
FI963779A (fi) | 1996-09-23 |
ATE198336T1 (de) | 2001-01-15 |
AU2192895A (en) | 1995-10-09 |
GR3035636T3 (en) | 2001-06-29 |
JP3536179B2 (ja) | 2004-06-07 |
EP0804483A1 (en) | 1997-11-05 |
EP0804483A4 (en) | 1998-05-20 |
WO1995025740A1 (en) | 1995-09-28 |
ES2154728T3 (es) | 2001-04-16 |
US5851523A (en) | 1998-12-22 |
DE69519748D1 (de) | 2001-02-01 |
CA2186004C (en) | 2008-09-23 |
PT804483E (pt) | 2001-06-29 |
DK0804483T3 (da) | 2001-02-12 |
EP0960622A2 (en) | 1999-12-01 |
EP0804483B1 (en) | 2000-12-27 |
FI963779A0 (fi) | 1996-09-23 |
JPH10504518A (ja) | 1998-05-06 |
AU698781B2 (en) | 1998-11-05 |
CN1150805A (zh) | 1997-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO963919L (no) | Isolerte peptider avledet fra MAGE-tumorrejeksjonsantigenforlöpere som komplekserer med HLA-A2-molekyler | |
NZ335485A (en) | Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof | |
CY1108083T1 (el) | Αντιγονα και συνθεσεις του neisseria meningitidis | |
PL374311A1 (en) | Methods for purifying protein | |
ES2129622T3 (es) | Receptores para interleuquina-10 de mamifero. | |
DE60139542D1 (de) | Methoden zur herstellung humaner monoklonaler antikörper | |
DE3750342D1 (de) | Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen. | |
ATE368688T1 (de) | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen | |
DE69824719D1 (de) | Cytokinähnlicher faktor-7 aus säugetieren | |
SE9602496D0 (sv) | Method and means for producing a fibrinogen binding protein and its use in biotechnology | |
DE69333382D1 (de) | Hyaluronan rezeptor (rezeptor durch hyaluronan verurzachte bewelichkeit) und hyaluronan bindende peptide | |
DE69735583D1 (de) | Semisynthetisches verfahren zur herstellung von didemninanalogen | |
DE60025704D1 (de) | Das goodpasture-antigen bindende protein | |
FI970071A0 (fi) | Eristetty nukleiinihapposekvenssi, joka koodaa HLA-A2:n esittämää tuumorihyljintäantigeeniä | |
DE69128039D1 (de) | Allergene aus roggenspreupollen | |
EP0990703A4 (en) | NEW POLYPEPTIDE, FOR CODING DNA AND THEIR USE | |
WO2001029220A3 (en) | Mage-a12 antigenic peptides and uses thereof | |
BR9911609A (pt) | Proteìnas e genes de moraxella catarrhalis, antìgenos, anticorpos e usos | |
AU653332B2 (en) | Synthetic peptides which contain sequences from factor VIIa, and the use thereof |